The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
MRI-PDFF treatment response criteria in nonalcoholic steatohepatitis
Hepatology. 2020 Nov 11. doi: 10.1002/hep.31624. Online ahead of print.
Rohit Loomba12
Author information
1NAFLD Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California at San Diego, La Jolla, United States.
2University of California at San Diego, Department of Family Medicine and Public Health, La Jolla, United States.
Abstract
Nonalcoholic steatohepatitis (NASH) is one of leading causes of chronic liver disease in the United States(1). NASH can lead to cirrhosis, end stage liver disease and hepatocellular carcinoma and has become one of the leading indications for liver transplant in the United States(2). Reversal of NASH and improvement of NASH-related fibrosis is a major unmet need in the field of liver disease. Several therapies have shown promise in the treatment of NASH-related fibrosis but there are no food and drug administration (FDA) and European Medicines Agency (EMA) approved therapies.